E. Maubec
- Dermatology top 0.2%
- Cutaneous lymphoproliferative disorders research 19
- Oncology top 2%
- Cutaneous Melanoma Detection and Management 25
- Cancer Immunotherapy and Biomarkers 21
- CAR-T cell therapy research 19
-
- Lymphoma Diagnosis and Treatment 11
- Epidemiology top 5%
- Nonmelanoma Skin Cancer Studies 20
- Immunology top 5%
- Immunotherapy and Immune Responses 12
-
- Melanoma and MAPK Pathways 13
E. Maubec
107 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Dermatology 1.1k
- Oncology 1.4k
- Pathology and Forensic Medicine 569
- Epidemiology 978
- Immunology 465
Countries citing papers authored by E. Maubec
This map shows the geographic impact of E. Maubec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Maubec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Maubec more than expected).
Fields of papers citing papers by E. Maubec
This network shows the impact of papers produced by E. Maubec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Maubec. The network helps show where E. Maubec may publish in the future.
Co-authorship network
The 25 scholars most cited alongside E. Maubec, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 3 | |
| 5 | 2023 | 3 | |
| 6 | 2022 | 6 | |
| 7 | 2021 | 14 | |
| 8 | 2019 | 28 | |
| 9 | 2016 | 9 | |
| 10 | 2015 | 87 | |
| 11 | 2013 | 79 | |
| 12 | Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skinbreakdown → | 2011 | 334 |
| 13 | 2010 | 98 | |
| 14 | 2009 | 59 | |
| 15 | 2009 | 10 | |
| 16 | 2008 | 11 | |
| 17 | 2007 | 25 | |
| 18 | 2007 | 4 | |
| 19 | 2007 | 144 | |
| 20 | Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. | 2005 | 79 |
About E. Maubec
E. Maubec is a scholar working on Dermatology, Oncology and Pathology and Forensic Medicine, having authored 112 papers that have together received 2.8k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (25 papers), Cancer Immunotherapy and Biomarkers (21 papers), Nonmelanoma Skin Cancer Studies (20 papers), CAR-T cell therapy research (19 papers), Cutaneous lymphoproliferative disorders research (19 papers), Melanoma and MAPK Pathways (13 papers), Immunotherapy and Immune Responses (12 papers) and Lymphoma Diagnosis and Treatment (11 papers). The work is most often cited by research in Dermatology (1.1k citations), Oncology (1.4k citations) and Pathology and Forensic Medicine (569 citations). E. Maubec has collaborated with scholars based in France, United States and Canada. Frequent co-authors include Marie‐Françoise Avril, Florent Grange, B. Crickx, Pierre Duvillard, Stéphane Dalle, Eduardo Marinho, Tony Petrella, M. Beylot‐Barry, Isabelle Scheer-Senyarich and Martine Bagot. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Dermatology, Cancers, Journal of Investigative Dermatology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.